Investigations of potent biocompatible metal-organic framework for efficient encapsulation and delivery of Gemcitabine: biodistribution, pharmacokinetic and cytotoxicity study.
Animals
Antimetabolites, Antineoplastic
/ pharmacokinetics
Apoptosis
Biocompatible Materials
/ chemistry
Cell Proliferation
Deoxycytidine
/ analogs & derivatives
Drug Carriers
/ chemistry
Drug Liberation
Humans
Male
Metal-Organic Frameworks
/ chemistry
Pancreatic Neoplasms
/ drug therapy
Rats, Wistar
Tissue Distribution
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Gemcitabine
Journal
Biomedical physics & engineering express
ISSN: 2057-1976
Titre abrégé: Biomed Phys Eng Express
Pays: England
ID NLM: 101675002
Informations de publication
Date de publication:
24 02 2020
24 02 2020
Historique:
entrez:
13
1
2021
pubmed:
14
1
2021
medline:
12
10
2021
Statut:
epublish
Résumé
Gemcitabine (GEM), a nucleoside analogue, is used for the treatment of various cancers. However, this drug possesses several limitations such as poor pharmacokinetics, metabolic degradation by cytidine deaminase, development of drug resistance, and schedule dependent toxicity. To circumvent these drawbacks, it can be entrapped in a suitable formulation for protection against metabolic degradation or urinary excretion. To this end, we have synthesized and investigated different iron (Fe-III)-based biocompatible metal-organic frameworks (MOFs), namely, MIL-101-NH
Identifiants
pubmed: 33438640
doi: 10.1088/2057-1976/ab73f7
doi:
Substances chimiques
Antimetabolites, Antineoplastic
0
Biocompatible Materials
0
Drug Carriers
0
MIL-101
0
Metal-Organic Frameworks
0
Deoxycytidine
0W860991D6
Gemcitabine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM